SS-31 and Vision:
What the Elamipretide Trials Actually Measured

SS-31—also called elamipretide or MTP-131—is a cardiolipin-binding tetrapeptide studied for mitochondrial diseases. Because the retina and retinal pigment epithelium carry an unusually high metabolic load, testing it in eye disease has a coherent biological rationale.

Mouse studies report restored or preserved visual function in aging and diabetic models. Small open-label dry-AMD studies reported modest best-corrected acuity gains and stronger low-luminance signals. But randomized Phase 2 ReCLAIM-2 missed both primary endpoints, and a topical trial in Leber hereditary optic neuropathy missed its primary visual-acuity endpoint.

No trial established SS-31 as a treatment for myopia, presbyopia or astigmatism. Claims that it changed a glasses prescription are anecdotes about endpoints the clinical program did not test.

Photoreceptors continuously renew outer segments, maintain ion gradients and process light. Their inner-segment ellipsoid zone is densely packed with mitochondria and appears as a clinically useful band on optical coherence tomography. Retinal pigment epithelial cells also depend heavily on mitochondrial energy production.

Elamipretide binds cardiolipin at the inner mitochondrial membrane and is reported to stabilize cristae, improve electron transport and reduce mitochondria-derived reactive oxygen species. That mechanism motivated formal programs in age-related macular degeneration and mitochondrial optic neuropathy; it does not originate with peptide-community anecdotes.

The clinical product and research-market SS-31 should not be treated as interchangeable. Trials used a characterized drug product at 40 mg subcutaneously or formulated ophthalmic drops. Identity, endotoxin burden and delivered quantity are separate uncertainties for research vials.

Reports tend to describe reduced light sensitivity, easier screen use, better dim-room vision, less visual fatigue or a general sense that vision became sharper. More expansive claims include improved eye-exam numbers or disappearing astigmatism.

Subjective low-light comfort could conceivably overlap with the low-luminance endpoints studied in diseased retinas. It still cannot establish a change in refractive error. Astigmatism primarily reflects corneal or lenticular optics, while presbyopia reflects age-related loss of lens accommodation. Neither is the target of a cardiolipin-binding mitochondrial therapy.

In aging mice, photopic spatial acuity declined beginning late in life. Elamipretide reportedly slowed that decline when started earlier and restored function over roughly two months when begun after impairment. Both systemic treatment and eye drops produced effects, while scotopic spatial vision changed little.

Earlier diabetic-retinopathy work found that MTP-131 reversed visuomotor decline in diabetic mice without correcting glucose or body weight. Healthy control mice did not receive a comparable “vision upgrade.” That pattern supports an effect under mitochondrial stress rather than universal enhancement.

These are disease-model findings. Mouse visuomotor behavior, retinal anatomy and dosing cannot establish that a healthy human will see more sharply.

ReCLAIM gave adults with dry AMD 40 mg subcutaneous elamipretide daily for 24 weeks. It was small, open-label and lacked a placebo group, so practice effects and expectation cannot be separated reliably from treatment.

Among published high-risk-drusen completers, mean best-corrected visual acuity improved 3.6 letters and low-luminance visual acuity improved 5.6 letters. Low-luminance reading showed a larger change. A noncentral geographic-atrophy cohort also reported modest acuity gains, even as atrophy continued to grow.

The low-luminance pattern is biologically interesting because it fits stressed photoreceptor and RPE function. It remains exploratory evidence rather than confirmation.

ReCLAIM-2 randomized 176 people with dry AMD and noncentral geographic atrophy to 40 mg subcutaneous elamipretide or placebo for 48 weeks. Mean low-luminance acuity change did not differ significantly, and the trial did not significantly slow square-root geographic-atrophy area on OCT.

Secondary, nominal findings favored elamipretide: reported progression of complete and partial macular ellipsoid-zone attenuation was slower, and more treated participants gained at least 10 low-luminance letters. These observations helped shape the ongoing Phase 3 ReNEW trial, which uses macular photoreceptor-loss rate as its primary endpoint.

The honest interpretation is mixed: unsuccessful prespecified primary outcomes alongside an anatomic photoreceptor-zone signal that warrants another trial. Until ReNEW reports, “SS-31 improves vision” is too broad.

ReSIGHT tested topical 1% elamipretide against vehicle in 12 people with the m.11778G>A Leber hereditary optic neuropathy mutation. It found no significant difference in the primary best-corrected visual-acuity endpoint. Post-hoc visual-field findings and open-label-extension observations are hypothesis-generating.

A topical program in Fuchs endothelial dystrophy did not produce a major published efficacy result. An expanded-access report involving two people with CPEO-plus and NARP described quality-of-life improvement, but a two-person case series cannot establish a vision effect.

These programs reinforce that elamipretide is a serious mitochondrial-eye candidate. They do not turn it into a refraction treatment.

For broader compound context, see the SS-31 research guide. The guide and this article serve different purposes: one covers the molecule generally; this review focuses on the vision claims and ophthalmology evidence.

The vision story is not empty. It follows a coherent line from cardiolipin and photoreceptor mitochondria, through mouse acuity rescue and open-label low-luminance gains, to a randomized Phase 2 trial that missed its functional and geographic-atrophy primary endpoints but reported slower ellipsoid-zone loss.

That is more evidence than most peptide-and-eyes claims have. It is also much narrower than the community narrative. The best current description is that elamipretide is a photoreceptor-bioenergetics candidate with mixed human functional evidence and an unresolved anatomic signal.

Anecdotes about easier low-light vision or less fatigue may describe something real, expectation, or both. They do not demonstrate that SS-31 changes corneal curvature, lens accommodation or a glasses prescription.